Interpace Biosciences (OTC: IDXG) reported Q2 EPS of ($0.93), $0.41 worse than the analyst estimate of ($0.52). Revenue for the quarter came in at $9.4 million versus the consensus estimate of $10.5 million.

For earnings history and earnings-related data on Interpace Biosciences (IDXG) click here.